Transient and Spontaneous Idiopathic Factor V Inhibitor

D. Laber, L. Bhupalam, G. Kloecker
{"title":"Transient and Spontaneous Idiopathic Factor V Inhibitor","authors":"D. Laber, L. Bhupalam, G. Kloecker","doi":"10.2174/1874276900802010086","DOIUrl":null,"url":null,"abstract":"We present the case of a 70-year-old woman found to have a prothrombin time (PT) of 26.8 seconds (s) and an activated partial thromboplastin time (PTT) of 71 s prior to an elective endoscopic retrograde cholangiopancreatography for symptomatic choledocholithiasis. She had no personal or family history of bleeding, thrombosis, autoimmune diseases, miscarriages, recent surgery or antibiotic use, and was not anticoagulated. Laboratory studies revealed a hemoglobin of 11 g/dl, and normal leucocyte count, platelet count, serum protein immunoelectrophoresis, D-dimer, fibrinogen, lupus anticoagulants and anticardiolipin antibodies. PT and PTT mixing studies revealed an inhibitor of a coagulation factor in the common pathway. Factor assays II, VIII and IX, were normal. Factor VII and X, both more than 50%, were difficult to quantify secondary to an inhibitor effect in the system, with increasing activity after dilution. Factor V had 5% activity. Factor V inhibitor was 1.6 Bethesda Units. Prednisone 60 mg was started and the ERCP successfully performed with no bleeding complication. Within 6 months the PT, PTT and factor V activity normalized and prednisone was tapered off.","PeriodicalId":89702,"journal":{"name":"Open journal of hematology","volume":"1 1","pages":"86-86"},"PeriodicalIF":0.0000,"publicationDate":"2008-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open journal of hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874276900802010086","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

We present the case of a 70-year-old woman found to have a prothrombin time (PT) of 26.8 seconds (s) and an activated partial thromboplastin time (PTT) of 71 s prior to an elective endoscopic retrograde cholangiopancreatography for symptomatic choledocholithiasis. She had no personal or family history of bleeding, thrombosis, autoimmune diseases, miscarriages, recent surgery or antibiotic use, and was not anticoagulated. Laboratory studies revealed a hemoglobin of 11 g/dl, and normal leucocyte count, platelet count, serum protein immunoelectrophoresis, D-dimer, fibrinogen, lupus anticoagulants and anticardiolipin antibodies. PT and PTT mixing studies revealed an inhibitor of a coagulation factor in the common pathway. Factor assays II, VIII and IX, were normal. Factor VII and X, both more than 50%, were difficult to quantify secondary to an inhibitor effect in the system, with increasing activity after dilution. Factor V had 5% activity. Factor V inhibitor was 1.6 Bethesda Units. Prednisone 60 mg was started and the ERCP successfully performed with no bleeding complication. Within 6 months the PT, PTT and factor V activity normalized and prednisone was tapered off.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
瞬时和自发的特发性因子V抑制剂
我们提出的情况下,一个70岁的妇女发现有凝血酶原时间(PT) 26.8秒(s)和活化部分凝血酶活时间(PTT) 71秒之前的选择性内镜逆行胆管造影症状胆总管结石。患者无出血、血栓形成、自身免疫性疾病、流产、近期手术或抗生素使用史,未使用抗凝药物。实验室检查显示血红蛋白为11 g/dl,白细胞计数、血小板计数、血清蛋白免疫电泳、d -二聚体、纤维蛋白原、狼疮抗凝血剂和抗心磷脂抗体正常。PT和PTT混合研究揭示了在共同途径中凝血因子的抑制剂。因子分析II、VIII和IX均正常。因子VII和因子X均超过50%,难以量化,次于系统中的抑制剂作用,稀释后活性增加。因子V有5%的活性。因子V抑制剂为1.6 Bethesda单位。泼尼松60mg开始,ERCP成功完成,无出血并发症。6个月内,PT、PTT和因子V活性恢复正常,强的松逐渐停用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Protective Role of Human Intravenous Immunoglobulin from Influenza AVirus Infection in Mice Novel Role of Ras-GTPase Activating Protein SH3 Domain-Binding ProteinG3BP in Adhesion and Migration of 32D Myeloid Progenitor Cells Cell Trafficking in Multiple Myeloma. Cell Trafficking in Chronic Lymphocytic Leukemia. Targeting the Oligomerization of BCR/ABL by Membrane Permeable Competitive Peptides Inhibits the Proliferation of Philadelphia ChromosomePositive Leukemic Cells
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1